Here you will find some information on the research chemical Ethylphenidate. Before reading we must stres that buy-methoxetamine.com only sell ethylphenidate for use as a research chemical, aromatic concentrate or optical brighter/cleaner pusposes only and it is strictly not for human consumption.
Our ethylphenidate is at abve 99.5% purity so is excellent for use in GC/MS reference pusposes. Please conduct your research responsibly and safely.
Ethylphenidate
CAS number: 57413-43-1 (as freebase); 19716-79-1 (as hydrochloride).
Systematic (IUPAC) name: ethyl phenyl(piperidin-2-yl)acetate.
Index name: 2-piperidineacetic acid, alpha-phenyl-, ethyl ester.
Other names and synonyms: ethylphenidate; EPH; ethyl 2-phenyl-2-(piperidin-2-yl)acetate; phenyl(piperidin-2-yl)acetic acid ethyl ester.
Description: Ethylphenidate (EPH) is a piperidine-based compound closely related to the pharmaceutical stimulant methylphenidate (MPH, sold under several brand names including "Ritalin" and "Concerta"). EPH is related to MPH in that they are both esters of ritalinic acid (phenyl(piperidin-2-yl)acetic acid); the former is the ethyl ester and the latter is the methyl ester. This structural likeness gives the two compounds a very similar pharmacodynamic profile.
EPH was first identified as a metabolite produced through coingestion of MPH and ethanol (alcohol). Its was subsequently included in a U.S. pharmaceutical patent (US6528530) encompassing a wide range of potentially medicinal MPH analogues, although it has not been further developed into a treatment.
Studies have shown that EPH behaves in a very similar manner to MPH, acting as a potent norepinephrine-dopamine reuptake inhibitor in animal test subjects. A 2004 study published in the Journal of Medicinal Chemistry (vol. 48, no. 8) noted that the two compounds have very similar dopaminergic interactions and near identical motor activity dose-response relationships at high and low doses. EPH was noted as having less activity at the norepinephrine transporter and both compounds were seen to be effectively inactive at the serotonin transporter.
Motor activity tests indicate that EPH has stimulatory effects comparable to MPH and the similarity between dopaminergic profiles suggests it will also share the euphoric and reinforcing effects of MPH. This is liable to give it a similar potential for illicit use so it is unlikely to ever be developed into a pharmaceutical treatment as it has not demonstrated any significant medical benefits over existing MPH-based treatments and appears to have the same potential for misuse.
Chemical properties (freebase):
Molecular Formula: C15H21NO2
Formula Weight: 247.33274
Composition: C(72.84%) H(8.56%) N(5.66%) O(12.94%)
Monoisotopic Mass: 247.157229 Da
Nominal Mass: 247 Da
Average Mass: 247.3327 Da
SMILES: CCOC(=O)C(C1CCCCN1)C2=CC=CC=C2
Chemical properties (hydrochloride):
Molecular Formula: C15H22ClNO2
Formula Weight: 283.79368
Composition: C(63.48%) H(7.81%) Cl(12.49%) N(4.94%) O(11.28%)
Monoisotopic Mass: 283.133907 Da
Nominal Mass: 283 Da
Average Mass: 283.7937 Da
SMILES: CCOC(=O)C(C1CCCCN1)C2=CC=CC=C2.Cl
Index name: 2-piperidineacetic acid, alpha-phenyl-, ethyl ester.
Other names and synonyms: ethylphenidate; EPH; ethyl 2-phenyl-2-(piperidin-2-yl)acetate; phenyl(piperidin-2-yl)acetic acid ethyl ester.
Description: Ethylphenidate (EPH) is a piperidine-based compound closely related to the pharmaceutical stimulant methylphenidate (MPH, sold under several brand names including "Ritalin" and "Concerta"). EPH is related to MPH in that they are both esters of ritalinic acid (phenyl(piperidin-2-yl)acetic acid); the former is the ethyl ester and the latter is the methyl ester. This structural likeness gives the two compounds a very similar pharmacodynamic profile.
EPH was first identified as a metabolite produced through coingestion of MPH and ethanol (alcohol). Its was subsequently included in a U.S. pharmaceutical patent (US6528530) encompassing a wide range of potentially medicinal MPH analogues, although it has not been further developed into a treatment.
Studies have shown that EPH behaves in a very similar manner to MPH, acting as a potent norepinephrine-dopamine reuptake inhibitor in animal test subjects. A 2004 study published in the Journal of Medicinal Chemistry (vol. 48, no. 8) noted that the two compounds have very similar dopaminergic interactions and near identical motor activity dose-response relationships at high and low doses. EPH was noted as having less activity at the norepinephrine transporter and both compounds were seen to be effectively inactive at the serotonin transporter.
Motor activity tests indicate that EPH has stimulatory effects comparable to MPH and the similarity between dopaminergic profiles suggests it will also share the euphoric and reinforcing effects of MPH. This is liable to give it a similar potential for illicit use so it is unlikely to ever be developed into a pharmaceutical treatment as it has not demonstrated any significant medical benefits over existing MPH-based treatments and appears to have the same potential for misuse.
Chemical properties (freebase):
Molecular Formula: C15H21NO2
Formula Weight: 247.33274
Composition: C(72.84%) H(8.56%) N(5.66%) O(12.94%)
Monoisotopic Mass: 247.157229 Da
Nominal Mass: 247 Da
Average Mass: 247.3327 Da
SMILES: CCOC(=O)C(C1CCCCN1)C2=CC=CC=C2
Chemical properties (hydrochloride):
Molecular Formula: C15H22ClNO2
Formula Weight: 283.79368
Composition: C(63.48%) H(7.81%) Cl(12.49%) N(4.94%) O(11.28%)
Monoisotopic Mass: 283.133907 Da
Nominal Mass: 283 Da
Average Mass: 283.7937 Da
SMILES: CCOC(=O)C(C1CCCCN1)C2=CC=CC=C2.Cl